Iterum Therapeutics
ITRM
ITRM was delisted on the 31st of March, 2026.
12 hedge funds and large institutions have $5.22M invested in Iterum Therapeutics in 2020 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 3 closing their positions.
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
20% more funds holding
Funds holding: 10 → 12 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
0.74% less ownership
Funds ownership: 2.3% → 1.56% (-0.74%)
29% less capital invested
Capital invested by funds: $7.33M → $5.22M (-$2.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
+$35.6K |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$17.8K |
| 3 |
WS
Wedbush Securities
Los Angeles,
California
|
+$10.6K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$10.1K |
| 5 |
Two Sigma Investments
New York
|
+$8.86K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$1.5M |
| 2 |
ML
McAdam LLC
Philadelphia,
Pennsylvania
|
-$14K |
| 3 |
BG
Bollard Group
Boston,
Massachusetts
|
-$2.04K |
ITRM Hedge Fund Activity: Q3 2020 in Review
12 institutional investors reported a position in Iterum Therapeutics (ITRM) for Q3 2020, worth a combined $5.22M — down 29% from $7.33M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new ITRM positions and 3 closed out — a net gain of 2 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Barclays, opening a new position worth an estimated $35.6K. The largest seller was Armistice Capital, exiting entirely with an estimated $1.5M sold.
- 12 institutional investors held Iterum Therapeutics (ITRM) as of Q3 2020, up from 10 in Q2 2020.
- Funds reported $5.22M of Iterum Therapeutics stock for Q3 2020, down 29% quarter-over-quarter.
- 5 funds opened new Iterum Therapeutics positions in Q3 2020 and 3 closed out, a net change of +2 holders.
- The largest Iterum Therapeutics buyer in Q3 2020 was Barclays, an estimated $35.6K added.
- The largest Iterum Therapeutics seller in Q3 2020 was Armistice Capital, an estimated $1.5M sold.
Based on aggregated 13F filings for Q3 2020.